Affiliation:
1. Department of Biotechnology PSG College of Technology, Biotechnology, Coimbatore, India
2. Department of Microbiology PSG Institute of Medical Science and Research, Microbiology, Coimbatore, India
Abstract
Background:
Carbapenem-resistant Enterobacteriaceae (CRE) has emerged as a global
threat with mortality risk ranging from 48%-71% worldwide. The emergence of MBL resistance is
threatening as carbapenem is one of the last line antibiotics. A total 24 variants of NDM resistance
raises a concern to the clinicians and epidemiologists worldwide.
Objective:
The study aims at identifying MBL resistance (NDM, IMP, VIM, GIM, SPM, and SIM)
and its coexistence in clinical isolates in a single tertiary care center.
Methodology:
Forty five clinical isolates characterized phenotypically for Carbapenem resistance
obtained from PSG Institute of Medical Science and Research (PSG IMSR), Coimbatore, between
February to March 2018 were taken for analysis.
Result:
Out of the 45 Clinical isolates, 38 isolates (84%) were detected as MBL carriers. VIM,
NDM, GIM, and SPM were the predominant resistance genes, with detection rates of 48.8%,
28.8%, 24.4%, and 22.2% respectively. Fifteen isolates were observed to harbor more than one
MBL gene in coexistence. Two isolates - U42 and R714 (K. pneumoniae) were found to harbor all
5 MBL variants in combination.
Conclusion:
33% of clinical isolates harboring multiple MBL variants is a concern in clinical settings.
The presence of SPM and GIM gene amongst isolates in this geographical location within
India is an indicator demanding continuous monitoring of these resistance determinants.
Publisher
Bentham Science Publishers Ltd.
Subject
Infectious Diseases,Pharmacology
Reference29 articles.
1. Dixit A.; Kumar N.; Kumar S.; Trigun V.; Antimicrobial resistance: Progress in the decade since emergence of New Delhi metallo-β-lactamase in India. Indian J Community Med 2019,44(1),4-8
2. Zilahi G.; Artigas A.; Martin-Loeches I.; What’s new in multidrug-resistant pathogens in the ICU? Ann Intensive Care 2016,6(1),96
3. Drawz S.M.; Bonomo R.A.; Three decades of beta-lactamase inhibitors. Clin Microbiol Rev 2010,23(1),160-201
4. Cornaglia G.; Giamarellou H.; Rossolini G.M.; Metallo-β-lactamases: a last frontier for β-lactams? Lancet Infect Dis 2011,11(5),381-393
5. Walsh T.R.; Toleman M.A.; Poirel L.; Nordmann P.; Metallo-beta-lactamases: the quiet before the storm? Clin Microbiol Rev 2005,18(2),306-325